Data on FDA-approved weight management medications dominate Obesity Week

Abstract

Last year was a pivotal year for approvals of weight management medications, with naltrexone plus bupropion (Contrave—Takeda) and liraglutide (Saxenda—Novo Nordisk) approved for chronic weight management in September and December, respectively. These two approvals were added to the drugs already marketed for weight management and weight loss—specifically, phentermine plus topiramate (Qsymia—Vivus) and lorcaserin (Belviq—Arena)—giving clinicians greater therapeutic options to help patients reach an ideal body weight.